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Ear wax removal interventions:
a systematic review and economic evaluation
Emma Loveman, Elena Gospodarevskaya, Andy Clegg, Jackie Bryant, Petra Harris,
Alex Bird, David A Scott, Peter Davidson, Paul Little and Richard Coppin
Clinical Intelligence
BACKGROUND
Excessive ear wax can lead to symptoms
such as hearing loss, tinnitus, itching,
vertigo, and pain. Treatment to remove ear
wax is generally carried out in primary care,
and recent estimates suggest that up to
2million ear irrigations are performed in
England andWales each year.1 This places a
considerable demand on GP surgeries.
A range of simple and often inexpensive
remedies and proprietary drops can be used
either to dissipate thewaxor soften it prior to
removal. Although removal through
irrigation usually occurs in primary care,
some people may self-treat. Treatments
offered often appear to be based on custom
and local practice, rather than an awareness
of the comparative effectiveness and costs of
the different alternatives. Although evidence
on the efficacy of different treatments has
been published, no study has examined both
clinical and cost-effectiveness. This report
summarises a systematic review and
economic evaluation of different approaches
to ear wax removal taken from a UK
perspective.
METHOD
Eleven electronic databases including
Cochrane, MEDLINE, and Embase were
searched until November 2008. Using
prespecifiedcriteria, studiesofany treatment
for the removal of earwax, in any population,
were included. Outcomes included hearing
loss, adequacy of clearance, quality of life,
and adverse events. Studies were
randomised controlled trials or controlled
clinical trials.Tworeviewersselectedstudies,
extracteddata,andassessedmethodological
quality, and studies were synthesised
narratively.
Existing economic evaluations were also
searched for and an exploratory economic
evaluation was undertaken. The model
estimated the cost-effectiveness of softeners
followed by irrigation in primary care, and
softeners followed by self-irrigation, relative
to no treatment and to each other. An NHS
perspective for theestimationof benefits and
costswasassumed. Thestudy focusedonan
adult population and assessed outcomes
over different time horizons. Only the
estimates of the incremental cost per
quality-adjusted life year (QALY) gained are
reported here.
RESULTS
Twenty-six clinical trials conducted in
primary care (14 studies), secondary care
(eight studies), or other care settings (four
studies) were included from an initial 188
identified references (Figure 1). A range of
interventions were used in the studies,
including different softeners and/or
irrigation. The timing of interventions and
follow-up assessments varied.
Characteristics of participants and choice
of outcome measures also differed
between the studies. Patient-relevant
outcomes were mostly subjective
measures of occlusion, presence of
symptoms, and adverse events. Lack of
homogeneity in methods, interventions,
and measures of outcomes precluded any
meaningful evidence synthesis.
Whenconsideringonlystudiesundertaken
inprimary care, and ignoringmethodological
shortcomings, there appears to be some
evidence of comparative benefits between
different interventions (Appendix1).However,
it is not possible to say that any one type of
softener is superior, based on the evidence
available.
Exploratory economic modelling of the
lifetime cost-effectiveness of softeners
followed by self-irrigation and softeners
followed by professional irrigation,
compared with no treatment, suggest
incremental cost-effectiveness ratios
(ICERs) of £24 450 (95% confidence interval
[CI] = 16 920 to 33 790) and £32 136 (95% CI
= 19 531 to 45 864) per QALY gained
respectively. When comparing the two active
treatments with each other, the estimated
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ICER ismore than £335 000 per QALY gained.
This suggests that softeners followed by self-
irrigationweremore likely to be cost-effective
than softeners followed by irrigation in
primary care, when compared with no
treatment. A number of sensitivity and
threshold analyses were undertaken. The
results did not appear to be sensitive to the
variation in thecostof self-irrigation, butwere
sensitive to variation in the estimates of
clinical effectiveness of softeners and the
utility associatedwith hearing loss. Caution is
required in the interpretation of the results of
the economic model, because of the paucity
of reliable data used to populate it.
DISCUSSION
Thestudy found limitedgood-qualityevidence,
which makes it difficult to differentiate
between the various methods for removing
earwax. Although the study was able to show
that softeners have an effect in clearing
earwax in their own right andasprecursors to
irrigation, it remains uncertain which specific
softeners are superior. While caution should
be taken in interpreting the results of the
economic evaluation, the study shows that
self-irrigation is likely to be more cost-
effective than professional irrigation. The
generalisability of the results, however,
depends on how the clinical pathways
assumed in the model are representative of
typical clinical practice, as these are known to
vary.
This findings are generally in line with
previous systematic reviews in this area.
However, this review differed because it
assessed studies by setting, the intention for
use of the softener, the populations, and the
follow-up. It assessed all methods of
treatment, including self-syringing; assessed
all available preparation comparisons; and
each study was assessed for methodological
quality. The researchwas undertaken to fill an
evidence gap identified as important by an
expert advisory panel of the National Institute
for Health Research Health Technology
Assessment Programme, so that
practitioners could be best informed about
treatments for ear wax.
Given the largenumberof people attending
primary care with ear wax, it was surprising
to find such limited good-quality evidence.
There was little in the way of consistency
among the included studies and many
studies omitted basic data. This cannot be
completely accounted for by the age of the
publications, as many have been published
since the advent of reporting standards for
trials. While rigorous, consistent methods of
critical appraisal and presentation were
applied in this study, these factors made it
difficult to summarise the results in a
meaningful way.
Further research is required to improve the
evidence base before policy and practice can
be reliably informed. Ideally, a well-
conducted randomised controlled trial and
economic evaluation could provide an
assessment of the different ways of providing
the service (that is, practice nurse provision
versus self-syringing) as well as the
effectiveness of the different methods of
removal. As part of this, it would be important
to assess first the acceptability of different
approaches, to ensure the most appropriate
research structure.
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Excluded
n = 157
Excluded n = 19
(3 intervention, 16 study design)
Identified on searching
(after duplicates removed)
n = 202
Titles and abstracts
inspected
Included studies n = 26
RCTs n = 22
CCTs n = 4
Full copies retrieved and
papers inspected
n = 45
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Figure 1. Flowchart of identification of studies for
inclusion in the systematic review of clinical
effectiveness. 
CCT = controlled clinical trial. 
RCT = randomised controlled trial.
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Appendix 1. Details of included studies undertaken in primary care settings 
Study details Comparison Key measure(s) Statistical significance
Audax®
Lyndon et al,2
RCT 1. Audax® (n = 19) Degree of impaction: none, mild, Not statistically significant
Age, mean (range) years: 52 (19–86) overall moderate, or severe (no P-value reported)
Sex, M:F for all patients: 19:17 2. Earex® (n = 17) Ease of syringing: not required, Statistically significant in favour of
Follow-up: 5 days easy, difficult, or impossible Audax® (P<0.005)
Cerumol®
Fahmy and Whitefield,3
CCT 1. Cerumol® (ears = 157) Wax dispersal without syringing Statistically significant in favour
Age: not reported of Exterol® (P<0.001)
Sex: not reported 2. Exterol® (ears = 129)
Follow-up: 1 week
Jaffé and Grimshaw,4
RCT 1. Cerumol® (n = 53) Number of people needing Statistically significant in favour
Baseline characteristics: syringing of Otocerol® (P = 0.05)
Age distribution (Group 1:Group 2): 2. Otocerol® (n = 53)
0–9 years: 0:1
10–19 years: 5:1
20–59 years: 31:35
60–89 years: 17:16
Sex, M:F:
1. 32:21
2. 25:28
Follow-up: patients asked to revisit GP after
three instillations
General Practitioner Research Group,5
RCT 1. Waxsol® (n = 47) Volume of water for syringing Not reported
Age groups, % of all patients:
10–30 years, 27 2. Cerumol® (n = 60) Ease of wax removal Not reported
31–50 years, 34
51–70 years, 31
71 years and over, 8
Sex: not reported
Follow-up: immediate
Dummer et al,6
RCT 1. Audax® (n = 27) Amount, colour, and consistency Not reported
Age, mean years: of wax
1. 51 2. Cerumol® (n = 23)
2. 55
Sex, M:F:
1. 18:9
2. 14:9
Follow-up: median number of days between
visits 1 and 2 was 4 days (range 3–7 days)
Triethanolamine polypeptide
Singer et al,7
RCT 1. DS (n = 27) TM visualisation: complete Not statistically significant
Age, mean years (SD): or incomplete
1. 38.7 (30.7) 2. TP (n = 23)
2. 46.1 (29.1)
Sex, M:F (%):
1. 16 (59):11 (41)
2. 16 (70):7 (30)
Follow-up: immediate
Meehan et al,8
RCT 1. DS (n = 15) TM visualisation: complete, Not reported
Age, mean years: 4.6 overall partial, clear
Sex, M:F overall: 24:24 2. TP (n = 17)
Follow-up: immediate
Also saline alone group
(n = 16)
... continued
Appendix 1 continued. Details of included studies undertaken in primary care settings
Study details Comparison Key measure(s) Statistical significance
Triethanolamine polypeptide 
Whatley et al,9
RCT 1. DS (n = 35) TM visualisation: complete Not reported 
Age, mean (SD):
1. 36.4 (19.1) monthsa 2. TP (n = 30)
2. 30.9 (15.2) months
Sex, M:F (%): Also saline alone group (n = 28)
1. 14:20 (41:59)
2. 13:17 (43:57)
Follow-up: immediate
Amjad and Scheer,10
RCT 1. TP (n = 40) Degrees of wax removal Not reported
Age: not reported
Sex: not reported 2. Carbamide peroxide (n = 40)
Follow-up: immediate
Sodium bicarbonate preparations
Carr and Smith,11
RCT 1. Aqueous sodium Mean change in degree of Not statistically significant
Age, mean years for all: bicarbonate (n = 35) cerumen (no P-value reported)
27.0
25.3 2. Aqueous acetic acid (n = 34)
Age, mean years for children:
1. 8.7
2. 7.26
Sex: not reported
Follow-up: 14 days
Dioctyl-medo
General Practitioner Research Group,12
RCT 1. Dioctyl-medo (n = 77) Volume of water for syringing Not reported
Age range, overall, years
M: 31–50 2. Oil-base alone (n = 73) Ease of wax removal
F: 51–70
Sex, all patients, M:F  1.3:1
Follow-up: immediate
Burgess,13
CCT 1. Dioctyl-medo (n = 33 ears) Ease of removing wax Not reported
Age range, years: 18–75 overall
Sex, M:F for all patients: 32:18 2. Maize oil capsules (n = 41 ears)
Follow-up: 2–7 days
Water
Eekhof et al,14
RCT
Age, mean years (SD): 51 (16) overall 1. Water (n = 22) Mean number of syringing Not statistically significant
Sex, M:F overall: 20:22 attempts (P = 0.18)
Follow-up: immediate for water group but 2. Self-administered oil (n = 20)
3 days for oil group
Pavlidis and Pickering,15
RCT 1. Wet syringing (n = 22 ears) Mean number of syringing Not tested
Age, mean years (SD): attempts
1. 63 (8) 2. Dry syringing (n = 17 ears)
2. 65 (20)
Sex, M:F (%):
1. 15 (68):7 (32)
2. 11 (65):6 (35)
Follow-up: immediate
aOne participant discontinued. CCT = controlled clinical trial. DS = docusate sodium. F = female. M = male. RCT = randomised controlled trial. 
SD = standard deviation. TM = tympanic membrane. TP = triethanolamine polypeptide.
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